SIX Swiss Exchange

Zur Rose Group AG: Shareholders approve all proposals

Retrieved on: 
Thursday, April 28, 2022
Board of directors, Committee, Pharmacy, Vice, SIX Swiss Exchange, Beauty, Technology, Mission statement, Telehealth, RTÉ Executive Board, Exercise, Compensation, Zur Rose Group, ISIN, ROSE, Board, Annual, CHF, Review, Health, Proxy, Media, Management, Director

All proposals concerning the elections and re-elections to the Board of Directors and the Compensation and Nomination Committee were approved.

Key Points: 
  • All proposals concerning the elections and re-elections to the Board of Directors and the Compensation and Nomination Committee were approved.
  • The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland.
  • With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care, as well as digital services relating to marketplaces, ecosystems, technology and telemedicine.
  • The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE).

Hashdex Announces Launch of the Hashdex Nasdaq Crypto Index Europe ETP

Retrieved on: 
Thursday, April 28, 2022
Crypto, CEO, HASH, SIX Swiss Exchange, ETF, Digital, NEW, ISIN, Nature, Ecosystem, ETP, Risk, Index, Cryptocurrency, Nasdaq, European

ZURICH and NEW YORK and RIO DE JANEIRO, April 28, 2022 /PRNewswire/ -- Hashdex, a leading global crypto-focused asset manager, today announced the upcoming launch of the Hashdex Nasdaq Crypto Index Europe exchange-traded product ("ETP") ISIN CH1184151731. The firm's first European product will be available on the SIX Swiss Exchange under the ticker symbol SIX: HASH SW starting Monday, May 2, 2022.

Key Points: 
  • ZURICH and NEW YORK and RIO DE JANEIRO, April 28, 2022 /PRNewswire/ -- Hashdex , a leading global crypto-focused asset manager, today announced the upcoming launch of the Hashdex Nasdaq Crypto Index Europe exchange-traded product ("ETP") ISIN CH1184151731.
  • The Hashdex Nasdaq Crypto Index Europe ETP (SIX: HASH SW) tracks the Nasdaq Crypto Index Europe(NCIE), an index designed to measure the performance of the overall digital asset market while remaining reflective of the ETP listing standards at specified European exchanges.
  • "The launch of HASH SW is a major milestone for Hashdex as we continue to deliver on our mission of providing global investors with access to the crypto asset class," said Marcelo Sampaio, Co-Founder & CEO of Hashdex.
  • With the support of Nasdaq, Hashdex is incredibly well-positioned to service the needs of investors with efficient strategies."

Four UBS Private Wealth Management Advisors in Greater Florida named to Barron's Top 1,200 Financial Advisors list

Retrieved on: 
Thursday, April 28, 2022
Barron's, Solution, UBS, NYSE, CFA, SIX Swiss Exchange, CFP, Investment banking, Baird (investment bank), Longevity, New, Trust, Financial adviser, Financial services

TAMPA, Fla., April 28, 2022 /PRNewswire/ -- UBS Private Wealth Management announced today that four of its advisors in the firm's Greater Florida market have been named to Barron's Top 1,200 Financial Advisors list for 2022.

Key Points: 
  • TAMPA, Fla., April 28, 2022 /PRNewswire/ -- UBS Private Wealth Management announced today that four of its advisors in the firm's Greater Florida market have been named to Barron's Top 1,200 Financial Advisors list for 2022.
  • "This award further reiterates our advisors' outstanding achievements and dedication to creating and executing long-term wealth management strategies to help achieve their clients' financial goals," said Gregory Kadet, Greater Florida Market Head at UBS Wealth Management USA.
  • The UBS advisors in the Greater Florida Private Wealth Management market named to the list:
    Christopher Aitken has been named to Barron's Top 100 Financial Advisors list, Top 1000 Financial Advisors list, and Top 1,200 Financial Advisors list every year eligible from 2006 to 2022.
  • Jason Stephens , CFP, has been named to Barron's Top 1,200 Financial Advisors list for nine consecutive years.

Zurich North America Selects Yellowbrick’s Cloud Data Warehouse Solution

Retrieved on: 
Thursday, April 28, 2022
Cloud, Solution, CEO, SAS, LinkedIn, Yellowbrick Data, Agriculture, Twitter, Zurich Insurance Group, Economics, GLOBE, SIX Swiss Exchange, Data warehouse, Technology, Acquisition, Data, Â, Data management platform, Group, OTCQX, Risk, Insurance, Biodiversity, TB, Risk management

MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Yellowbrick Data, the leader in Distributed Data Cloud architecture for data warehousing, today announced that Zurich North America (Zurich), one of the largest providers of insurance solutions and services, selected Yellowbrick to replace its legacy on-premise data warehouse with a robust cloud-based architecture.

Key Points: 
  • MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Yellowbrick Data, the leader in Distributed Data Cloud architecture for data warehousing, today announced that Zurich North America (Zurich), one of the largest providers of insurance solutions and services, selected Yellowbrick to replace its legacy on-premise data warehouse with a robust cloud-based architecture.
  • In choosing a cloud data warehouse provider, we were focused on two main things: price for performance and ease of migration.
  • Yellowbrick met our needs in both key areas and has begun to establish a strong relationship with us, said Denise Birdsell, Head of IT Data Management at Zurich at Zurich North America.
  • Yellowbricks elastic data warehouse helps Zurich gain critical business insight from their data including validating insurance pricing and evaluating data on policies sold and claims made, said Neil Carson, CEO and Co-founder at Yellowbrick.

Casa de Alba Foundation Selects WISeKey’s WISe.Art NFT Market Place and Luminaries21 for the Digital Transformation of one the Best Private Collections of Cultural Heritage NFT produced by Pedro Sandoval

Retrieved on: 
Thursday, April 28, 2022
House, Christopher Columbus (1923 film), Duke, NFT, Big data, Computer, Non-fungible token, Sale, Internet, Semiconductor, Collection, Human, Partnership, History, SIX Swiss Exchange, WIHN, Fulcrum, AI, IOT, Digital, Painting, Method, City, WKEY, NASDAQ, World Leaders, Artificial intelligence, Animation, Culture, Museum, Film, Cryptocurrency, Aluminium, Blockchain, Metaverse

Throughout history, its prevailing position has allowedCasa de Alba Foundationto interact with the best in the world of Spanish arts and letters.

Key Points: 
  • Throughout history, its prevailing position has allowedCasa de Alba Foundationto interact with the best in the world of Spanish arts and letters.
  • Responding to thehighestquality requirementsof NFTs buyers and sellers of high-value goods, theWISe.Artplatform is developing into a fully-fledged vettedmarketplace.
  • This first digitalNFTartworkwith Casa de Alba Foundation and Luminaries21,was created by Pedro Jos Sandoval,aSpanish-Venezuelan artist based in Madrid, Spain.
  • About Fundacion Casa de Alba:
    The Casa de Alba Foundation is a Spanish institution dedicated to culture.

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

Retrieved on: 
Thursday, April 28, 2022
Clinical, Hospital, U.S. Securities and Exchange Commission, LinkedIn, Nephrology, List of Hindawi academic journals, Iron, Outcome (probability), Association, Patient, Twitter, FDA, Risk, Kidney, Therapy, Chronic kidney disease, SIX Swiss Exchange, International Journal of Nephrology and Renovascular Disease, Private Securities Litigation Reform Act, Quality of life, Primary biliary cholangitis, Company, Annual report, Uremic pruritus, Security (finance), Marketing, Dialysis, Mortality, ISIN, Itch, Fresenius Medical Care, Vifor Pharma, Canadian International Council, Health, CKD, Atopic dermatitis, Instagram, Pharmaceutical industry, Health insurance

Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives.

Key Points: 
  • Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives.
  • For more information, please visit viforpharma.com
    Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus.
  • The Companys novel KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
  • 4 Mathur VS, et al.A longitudinal study of Uremic Pruritus in hemodialysis patients.Clin J Am Soc Nephrol.2010; 5(8):1410-1419.

Addex to Present at the Swiss Biotech Day 2022

Retrieved on: 
Thursday, April 28, 2022
Blepharospasm, Drug discovery, Protein, CEO, Biotechnology, Georgia World Congress Center, Nasdaq, L-DOPA, ADX71149, GABAB, Therapy, SIX Swiss Exchange, Congress Center, Dystonia, Allosteric regulation, Clinical trial, Neurodegeneration, PAM, Janssen Pharmaceuticals, Glutamate (neurotransmitter), Epilepsy, PTSD, Lists of diseases, NAM, Dyskinesia, Glutamic acid, American depositary receipt, Glutamate receptor, Psychosis, CEST, Pharmaceutical industry

Geneva, Switzerland, April 28, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2022 taking place May 2 - 3, 2022, at the Congress Center in Basel, Switzerland.

Key Points: 
  • Geneva, Switzerland, April 28, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2022 taking place May 2 - 3, 2022, at the Congress Center in Basel, Switzerland.
  • In his live presentation, scheduled for 15:45 16:00 CEST, on May 2, 2022, in the Osaka/Samarkand room on the third floor, Mr. Dyer will provide a corporate update and discuss recent developments at Addex.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.

Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase Chemical Diversity Center

Retrieved on: 
Wednesday, April 27, 2022
Pharmacology, Infection, Isavuconazonium, Achievement, Assistant Secretary of Defense for Health Affairs, PDDI, FCCDC, Research, Mycosis, Patient, SIX Swiss Exchange, Biomedical Research, PABC, Communication, Basilea Pharmaceutica, Assistant, Cancer, Defense, ADME, Pharmaceutical industry

Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, said: This agreement shows our commitment to implementing our new corporate strategy, with a future focus on anti-infectives.

Key Points: 
  • Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, said: This agreement shows our commitment to implementing our new corporate strategy, with a future focus on anti-infectives.
  • The profile and the broad antifungal activity of the lead compound shown in preclinical studies are very promising.
  • Under the terms of the agreement, Basilea is granted an exclusive worldwide license to FCCDCs antifungal program.
  • Fox Chase Chemical Diversity Center, Inc. (FCCDC) is based in Doylestown, Pennsylvania, USA, at the Pennsylvania Biotechnology Center (PABC) and is affiliated with the Pennsylvania Drug Discovery Institute (PDDI).

21Shares launches BOLD, the world's first Bitcoin and Gold ETP

Retrieved on: 
Wednesday, April 27, 2022
Financial Services and Markets Act 2000, ETP, Research, BOLD, Securities Act of 1933, FSMA, Prospectus, SFSA, General officer, Multimedia, Issuer, FCA, Adoption, Finance, EEA, Bitcoin network, Company, Cryptocurrency exchange, Advertising, Solution, Partnership, CEO, Growth, SIX Swiss Exchange, Ecosystem, Financial services, Communication, Financial Conduct Authority, Bank account, Exchange-traded product, Onyx, AG, Person, NEW, Risk, Bank, Cryptocurrency, Bitcoin, EU, Order, Gold

The 21Shares ByteTree BOLD ETPwill track a new customized benchmark/index comprising Bitcoin and Gold via monthly rebalancing.

Key Points: 
  • The 21Shares ByteTree BOLD ETPwill track a new customized benchmark/index comprising Bitcoin and Gold via monthly rebalancing.
  • "At 21Shares, we are excited to introduce the public to the world's first Bitcoin and Gold ETP.
  • This hybrid product combines the traditional value of Gold with the promising return rates of Bitcoin, which is considered by many as the new Gold, said Hany Rashwan, CEO & co-founder at 21Shares.
  • With BOLD, we are entering completely new territory and again demonstrate the pioneering spirit of 21Shares within the ever-evolving crypto space."

94th Vifor Pharma Group Annual General Meeting

Retrieved on: 
Tuesday, April 26, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Board, SIX Swiss Exchange, The Annual Report, Annual, Marketing, COVID-19, Fresenius Medical Care, CHF, Annual report, Proxy, Patient, Nephrology, Executive Committee, Dialysis, ISIN, Health, National Executive Committee of the Labour Party, Iron, Vifor Pharma, CSL, Director

At todays 94th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors.

Key Points: 
  • At todays 94th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors.
  • Shareholders approved the Annual Report and the Annual Financial Statements of Vifor Pharma Ltd. and the consolidated Financial Statements of Vifor Pharma for 2021 by a large majority, as well as the 2021 Remuneration Report in a consultative vote.
  • Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives.
  • Vifor Pharma Group holds a leading position in all its core business activities and includes the companies: Vifor Pharma, Sanifit Therapeutics, and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).